Dong-Ying Xie
Overview
Explore the profile of Dong-Ying Xie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu L, Li X, Deng K, Lin B, Deng H, Xie D, et al.
Liver Res
. 2025 Feb;
7(2):136-144.
PMID: 39958952
Background And Aims: The primary goal of chronic hepatitis B (CHB) treatment is to reduce hepatitis B surface antigen (HBsAg). T helper 17 (Th17) and regulatory T (Treg) cells are...
2.
Pang X, Li X, Zhu W, Huang R, Mo Z, Huang Z, et al.
Antiviral Res
. 2023 Apr;
213:105592.
PMID: 37004734
HBsAg seroclearance, the ideal aim of anti-hepatitis B virus (HBV) treatment, cannot be achieved easily. Anemia is another common issue for chronic hepatitis B (CHB) patients, which leads to elevation...
3.
Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients
Chu J, Huang Y, Xie D, Deng H, Wei J, Guan Y, et al.
J Viral Hepat
. 2022 Jun;
29(9):765-776.
PMID: 35718996
Combination therapy with pegylated interferon (PEG-IFN) and nucleos(t)ide analogues (NAs) can enhance hepatitis B surface antigen (HBsAg) clearance. However, the specific treatment strategy and the patients who would benefit the...
4.
Wu L, Li X, Deng H, Xie D, Gu Y, Bi Y, et al.
Virus Res
. 2021 Dec;
309:198657.
PMID: 34919970
Background: The relationship between the serum transforming growth factor (TGF)-β level and HBsAg loss has not been clearly elaborated in patients with chronic hepatitis B (CHB). Methods: Two cohorts of...
5.
Xu W, Li Y, Li J, Mei Y, Chen Y, Li X, et al.
Gastroenterol Rep (Oxf)
. 2021 Sep;
9(4):313-322.
PMID: 34567563
Background: Chronic hepatitis B (CHB) patients have a high virological relapse rate after cessation of nucleos(t)ide analog (NA) treatment, but the clinical outcome remains unclear. This study aimed to investigate...
6.
Wu Z, Tan L, Gan W, Mo Z, Chen D, Wang P, et al.
Ann Transl Med
. 2021 Apr;
9(5):414.
PMID: 33842635
Background: The seroconversion of the hepatitis B antigen is the ideal outcome for long-acting interferon-pegylated interferon-α (Peg-IFN-α) treatment among patients with chronic hepatitis B (CHB). B-cell response plays an important...
7.
Tan L, Wu Z, Zhao C, Chen S, Wang P, Gao Z, et al.
Ann Palliat Med
. 2020 Nov;
10(2):1388-1395.
PMID: 33183037
Background: This study aimed to investigate the dynamic changes of serum HBV DNA and hepatitis B surface antigen (HBsAg) titers apportioned by the same hepatic parenchyma cell volume (HPCV) at...
8.
Huang Y, Zhao Q, Wu L, Xie D, Gao Z, Deng H
Can J Gastroenterol Hepatol
. 2018 Nov;
2018:1020925.
PMID: 30402448
T follicular helper cells (Tfh cells) affect essential immune pathogenesis in chronic hepatitis B virus (HBV) infection. The CCR7PD-1 Tfh subset has a partial Tfh effector phenotype and is associated...
9.
Xu W, Zhang Q, Zhu X, Lin C, Chen Y, Deng H, et al.
Can J Gastroenterol Hepatol
. 2018 Jun;
2018:1817680.
PMID: 29862225
Background And Aims: We aimed to ascertain the feasibility and safety of NA cessation, the status of patients after cessation, and the predictive factors for relapse and subsequent retreatment. Methods:...
10.
Lin B, Chen J, Qiu W, Wang K, Xie D, Chen X, et al.
Hepatology
. 2017 Apr;
66(1):209-219.
PMID: 28370357
Conclusion: Peripheral infusion of allogeneic bone marrow-derived MSCs is safe and convenient for patients with HBV-related ACLF and significantly increases the 24-week survival rate by improving liver function and decreasing...